Industry Overview - The dental medical equipment industry is experiencing rapid growth in China, driven by an aging population and increasing disposable income, leading to heightened awareness of oral health [1][8] - The market size for dental medical equipment in China is projected to grow from 22.3 billion yuan in 2020 to 41.2 billion yuan in 2024, with a compound annual growth rate (CAGR) of 16.59% [1][8] - The global dental medical equipment market is also expanding, expected to increase from 14.6 billion USD in 2020 to 20.7 billion USD in 2024, with a CAGR of 9.12% [6] Market Dynamics - The demand for dental medical services is rising, leading to a robust growth phase for the dental equipment market in China [1][8] - The domestic market for dental medical equipment is forecasted to reach 47.9 billion yuan by 2025 [1][8] - The domestic CBCT (Cone Beam Computed Tomography) market is becoming a focal point, with the localization rate expected to rise from 16.3% in 2020 to 56.44% in 2024 [10][18] Competitive Landscape - Major players in the Chinese dental medical equipment market include Xinhua Medical, Meiya Optoelectronics, Times Angel, and Kangzhong Medical [2][12] - The industry is currently reliant on imports for 90% of its dental equipment, particularly in the mid-to-high-end segments, but there is a significant opportunity for domestic companies to replace imports [12][18] - Key products from leading companies include CBCT systems, dental sterilization equipment, and implant devices [14][16] Development Trends - There is a notable acceleration in domestic replacement and technological breakthroughs, particularly in CBCT, with expectations for further advancements in high-end sectors [18] - The integration of digital and intelligent technologies is transforming the dental medical equipment industry, enhancing diagnostic efficiency and patient experience [19] - The market is witnessing a segmentation in demand, with older populations driving the need for dental implants and younger consumers pushing for aesthetic treatments like invisible orthodontics [20]

Meeting Details - The annual general meeting of Jiangsu Kangzhong Digital Medical Technology Co., Ltd. was held on May 16, 2025, at the company's conference room in Suzhou Industrial Park [1] - A total of 27 ordinary shareholders attended the meeting, holding 39,697,653 voting rights, which represents 45.4252% of the total voting rights after excluding 737,722 shares without voting rights [1] Voting Results - All non-cumulative voting proposals were approved with significant majority support, including: - Proposal 1: 39,522,267 votes in favor (99.5582%), 175,086 against (0.4410%), and 300 abstentions (0.0008%) [1] - Proposal 2: 39,422,555 votes in favor (99.3070%), 275,098 against (0.6930%), and no abstentions [1] - Proposal 3: 39,520,067 votes in favor (99.5527%), 177,586 against (0.4473%), and no abstentions [1] - Proposal 4: 39,420,055 votes in favor (99.3007%), 277,598 against (0.6993%), and no abstentions [1] Legal Compliance - The meeting was conducted in accordance with the Company Law and the company's articles of association, ensuring its legality and validity [1][5] - The legal representatives confirmed that the meeting's procedures and voting results complied with relevant laws and regulations [4][5]

Core Viewpoint - The legal opinion letter confirms that the 2024 annual general meeting of Jiangsu Kangzhong Digital Medical Technology Co., Ltd. was convened and conducted in compliance with relevant laws and regulations, ensuring the legitimacy and effectiveness of the meeting's procedures and voting results [1][17]. Group 1: Meeting Convening and Notification - The board of directors announced the meeting on April 26, 2025, in accordance with the relevant regulations [4]. - The notice for the meeting was sent out 20 days in advance, detailing the time, location, voting methods, and agenda [6]. - The notice and proposals for the meeting complied with the legal requirements [5][6]. Group 2: Attendance and Qualifications - A total of 6 attendees represented 21,624,628 shares, accounting for 24.7446% of the voting shares [7]. - The qualifications of the attendees, including shareholders, directors, supervisors, and legal representatives, were verified and deemed valid [8]. Group 3: Voting Procedures and Results - The voting process was conducted according to legal standards, with no amendments to the proposed resolutions during the meeting [9]. - The meeting approved several resolutions, including the 2024 annual report and financial statements, with voting results indicating significant support [10][11][12]. - Special resolutions were passed with more than two-thirds approval from the attending shareholders [17].

Group 1 - The company will hold an investor briefing on May 26, 2025, from 10:00 to 11:00 AM to discuss its 2024 annual and 2025 first-quarter performance [1][2] - The briefing will be conducted in an online interactive format via the Shanghai Stock Exchange Roadshow Center [1][2] - The company encourages investors to submit questions in advance for discussion during the briefing [1][2] Group 2 - Key participants in the briefing will include the Chairman and General Manager Jianqiang Liu, CFO Zhang Ping, Board Secretary Yin Sheng, and Independent Director Cheng Xingbao [2] - Investors can participate by logging into the Shanghai Stock Exchange Roadshow Center and submitting questions through the designated section or via the company's email [2][3] - The company’s securities affairs department is available for further inquiries, with contact details provided [3]

Group 1 - The company announced the resignation of employee representative director Ling Jun due to work adjustments, effective immediately, and he will continue to serve in a research-related role [1][2] - The company held an employee representative meeting on May 16, 2025, to elect Ye Xiaoming as the new employee representative director and member of the audit committee, with a term lasting until the end of the current board's term [2] - The audit committee's composition changed, with Ye Xiaoming replacing Ling Jun as a member, while Guo Jiangguang remains the chairman and Cheng Xingbao continues as a member [2] Group 2 - Ye Xiaoming, born in 1985, has a background in IT engineering and has held various positions within the company, including Vice President of Sales, and is now appointed as the employee representative director and audit committee member [2]

证券代码：688607 证券简称：康众医疗 公告编号：2025-024 公司职工代表大会近日收到公司职工代表董事凌骏先生的辞任函，凌骏先 生因工作调整原因，申请辞去公司第三届董事会职工代表董事职务，辞职生效 后，凌骏先生不再担任第三届董事会审议委员会委员，但仍在公司担任与其工 作职责相关的研发职务。凌骏先生在任职期间勤勉尽责，恪尽职守，公司及董 事会对凌骏先生在公司任职期间所做出的贡献表示感谢。 （二）关于补选职工代表董事的情况说明 为完善公司治理结构，保证公司董事会的规范运作，根据《公司章程》等 内控制度的相关规定，公司于 2025 年 5 月 16 日召开职工代表大会审议通过了 《关于职工代表董事辞职暨选举职工代表董事的议案》，同意选举叶晓明先生为 公司第三届董事会职工代表董事，叶晓明先生任期自职工代表大会审议通过之 日起至第三届董事会任期届满之日止。 二、公司第三届董事会审计委员会成员变更情况 江苏康众数字医疗科技股份有限公司 关于变更职工代表董事暨审计委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ...

证券代码：688607 证券简称：康众医疗 公告编号：2025-022 江苏康众数字医疗科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次说明会将于 2025 年 5 月 26 日（星期一）10:00-11:00 在上证路演中心 （http://roadshow.sseinfo.com/）在线召开。 三、参加人员 会议召开时间：2025年5月26日（星期一）10:00-11:00 会议召开地点：上证路演中心（http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 重要内容提示： 江苏康众数字医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 26 日披露了《2024 年年度报告》《2025 年第一季度报告》。为加强与投资者的 深入交流，使投资者更加全面、深入地了解公司 2024 年度及 2025 年第一季度经 营成果、财务状况，公司拟以网络文字互动方式召开 2024 年度暨 2025 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688607 证券简称：康众医疗 公告编号：2025-023 江苏康众数字医疗科技股份有限公司 2024年年度股东大会决议公告 （一） 股东大会召开的时间：2025 年 5 月 16 日 （二） 股东大会召开的地点：苏州工业园区星湖街 218 号生物纳米园 B3 楼 501 室公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 27 | | --- | --- | | 普通股股东人数 | 27 | | 2、出席会议的股东所持有的表决权数量 | 39,697,653 | | 普通股股东所持有表决权数量 | 39,697,653 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 45.4252% | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 45.4252% | 注：公司具有表决权股票总数已剔除公司 ...

北京市中伦律师事务所 关于江苏康众数字医疗科技股份有限公司 2024 年年度股东大会的 在本法律意见书中，本所律师对本次股东大会的召集和召开程序、出席会议 人员和会议召集人资格、会议表决程序及表决结果是否符合《公司法》《证券法》 《股东会规则》等法律、法规、规范性文件和《公司章程》《股东大会议事规则》 的有关规定发表意见。 本法律意见书仅供见证公司本次股东大会之目的使用，不得用作任何其他目 的。 为出具本法律意见书，本所委派律师（以下简称"本所律师"）列席了公司 本次股东大会，并根据现行法律、法规的有关规定及要求，按照律师行业公认的 业务标准、道德规范和勤勉尽责精神，对公司提供的与本次股东大会召开有关的 文件和事实进行了核查和验证，在此基础上，本所律师对本法律意见书出具之日 及以前所发生的与本次股东大会相关事实发表法律意见如下： 法律意见书 致：江苏康众数字医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受江苏康众数字医疗科技股 份有限公司（以下简称"公司"）的委托，就公司 2024 年年度股东大会（以下 简称"本次股东大会"）召开的有关事宜，根据《中华人民共和国公司法》（以 下简称"《公司法 ...

江苏康众数字医疗科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688607 证券简称：康众医 疗 江苏康众数字医疗科技股份有限公司 2024 年年度股东大会会议资料 二〇二五年五月 江苏康众数字医疗科技股份有限公司 2024 年年度股东大会会议资料 江苏康众数字医疗科技股份有限公司 2024 年年度股东大会会议资料 目录 | 2024 年年度股东大会会议须知 | | 3 | | --- | --- | --- | | 2024 年年度股东大会会议议程 | | 5 | | 2024 年年度股东大会议案 | | 7 | | 议案一：关于公司《2024 | 年年度报告》及其摘要的议案 | 8 | | 议案二：关于公司《2024 | 年度董事会工作报告》的议案 | 9 | | 议案三：关于公司《2024 | 年度监事会工作报告》的议案 | 14 | | 议案四：关于公司《2024 | 年度财务决算报告》的议案 | 18 | | 议案五：关于公司《2024 | 年年度利润分配方案》的议案 | 24 | | 议案六：关于续聘 | 年度审计机构的议案 2025 | 26 | | 议案七：关于 2025 | ...